UCB Pharma SA
Clinical trials sponsored by UCB Pharma SA, explained in plain language.
Pharmaceutical company focused on neurology and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a Two-Drug combo stop early rheumatoid arthritis in its tracks?
Disease control CompletedThis trial is testing whether combining certolizumab pegol, an injectable biologic, with methotrexate, a standard oral medication, can help adults with early active rheumatoid arthritis achieve and maintain remission. Participants are newly diagnosed, have not yet taken disease-m…
Phase 3 • Sponsor: UCB Pharma SA • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New epilepsy drug shows promise for kids in Long-Term safety trial
Disease control CompletedThis study looked at the long-term safety of brivaracetam, a seizure medication, when added to existing treatment in 257 children with epilepsy. The main goal was to track side effects over time. Researchers also measured how well the drug controlled seizures. The results help do…
Phase 3 • Sponsor: UCB Pharma SA • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC